Form 4: Marimed CCO Ryan Crandall Converts RSUs

Marimed Inc.'s Chief Commercial Officer, Ryan Crandall, converted restricted stock units into common stock and sold a portion for tax obligations.

Summary

• Ryan Crandall, Chief Commercial Officer of Marimed Inc. (MRMD), reported changes in his beneficial ownership of common stock.
• On September 28, 2025, Mr. Crandall acquired 6,046 shares of common stock through the conversion of Restricted Stock Units (RSUs) at an exercise price of $0.
• Concurrently, 1,775 shares of common stock were disposed of to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.143 per share.
• Following these transactions, Mr. Crandall directly beneficially owns 731,938 shares of common stock.
• He also directly beneficially owns 18,140 derivative securities in the form of Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While some shares were sold for tax, the primary event is the vesting and conversion of RSUs, which increases the executive's direct ownership and aligns interests. This is a routine, expected event.

Positives

• The conversion of RSUs into common stock increases the Chief Commercial Officer's direct ownership in the company, aligning his interests further with shareholders.
• The remaining 18,140 RSUs indicate a continued long-term incentive for the executive.

Negatives

• A portion of the vested shares (1,775 shares) was sold to cover tax withholding obligations, resulting in a reduction of direct common stock ownership from the gross vested amount.

Future Outlook

The remaining 18,140 Restricted Stock Units (RSUs) held by Ryan Crandall are scheduled to vest in three equal installments on March 28, 2026, September 28, 2026, and March 28, 2027, in accordance with the award agreement.

Industry Context

This filing is a routine insider transaction report and does not provide specific industry-wide context or trends. It reflects standard executive compensation practices within publicly traded companies.

Stakeholder Impact

• Shareholders: The increase in direct common stock ownership by a key executive may be viewed positively as it indicates continued alignment of interests with shareholders. The sale for tax purposes is a routine event and not indicative of a lack of confidence.

Next Steps

• Future vesting of remaining 18,140 Restricted Stock Units (RSUs) on March 28, 2026, September 28, 2026, and March 28, 2027.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale for tax withholding. Such transactions are generally pre-scheduled and do not typically indicate a material change in the company's fundamentals or outlook. Therefore, a 'hold' recommendation is appropriate as this event alone does not warrant a change in investment thesis.

Keywords

Marimed, MRMD, Ryan Crandall, Form 4, Restricted Stock Units, RSU conversion, insider transaction, beneficial ownership, Chief Commercial Officer